Realizing the Therapeutic Potential of the Endocannabinoid System

Abide is a clinical-stage biopharmaceutical company committed to realizing the therapeutic value of first-in-class endocannabinoid modulators to transform the lives of patients with serious unmet medical needs. Our lead program focuses on potentiating the endocannabinoid system with highly selective inhibitors of the enzyme monoacylglycerol lipase (MGLL) to treat a broad range of neurological diseases. Our lead candidate, ABX-1431, is in a Phase 2 trial in Tourette Syndrome and entering Phase 2 in other neurological diseases.

First-in-Class Pipeline of Serine Hydrolase Inhibitors

MGLL is an emblematic member of a large family of enzymes called serine hydrolases that serve as key regulators of diverse signaling pathways in human physiology and disease and accordingly represent a rich source of potential first-in-class medicines. In addition to our clinical programs targeting MGLL to address neurological diseases, including pain, Abide has a rich preclinical pipeline of inhibitors targeting other serine hydrolases for neurological diseases, as well as liver disease and inflammation.

Unique Discovery Platform

Abide’s platform accelerates discovery of novel medicines by leveraging proprietary chemical probes and libraries that target the unique catalytic mechanism shared by serine hydrolases. This allows us to simultaneously determine the functions of serine hydrolases in human disease and develop selective inhibitors of these enzymes as candidate therapeutics.